Pharmacy news
Humana announces changes to 2020 formulariesPharmacy news
Find pharmacy-related safety alerts, drug recall and new generic drug announcements and other medication information.
Notifications and pre-authorizations
Additional notifications
Drug recall notice for Natpara
Information about the launch of generic Symbicort HFA inhaler
Effective Jan. 11, 2020, generic Symbicort HFA inhaler (budesonide/formoterol HFA inhaler) is not covered or may require prior authorization (PA) for Medicare and commercial patients; brand Symbicort HFA inhaler will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 1-800-555-CLIN (1-800-555-2546), Monday through Friday, 8 a.m. to 8 p.m. Eastern time. Prescribers in Puerto Rico should call 1-866-488-5991.
Information about the launch of authorized generic insulin aspart and insulin aspart mix
Effective Dec. 14, 2019, authorized generics for NovoLog and NovoLog Mix (insulin aspart and insulin aspart mix) came to market. They are currently under evaluation for Humana’s Medicare Advantage prescription drug plans, Medicare Part D plans and commercial plans; brand NovoLog and NovoLog Mix will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 1-800-555-CLIN (1-800-555-2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 1-866-488-5991.
Information about the launch of generic Afinitor
Effective Dec. 14, 2019, generic Afinitor (everolimus) is not covered on Humana’s Medicare Advantage prescription drug and Part D plans; brand Afinitor will continue to be covered with prior authorization (PA) and can be filled for the patient.
Prescribers with questions regarding this may call 1-800-555-CLIN (1-800-555-2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 1-866-488-5991.
2019–2020 reimbursement rates for flu and pneumonia vaccines
Humana has announced 2019–2020 reimbursement rates for network pharmacies providing influenza and pneumococcal vaccinations.
For questions regarding the coverage of these vaccines, please call the number on the back of member’s ID card.
Information about the launch of generic Jadenu
Effective Dec. 6, 2019, generic Jadenu (deferasirox) is not covered for Medicare patients; brand Jadenu will continue to be covered with prior authorization (PA) and can be filled for the patient.
Prescribers with questions regarding this may call 1-800-555-CLIN (1-800-555-2546), Monday through Friday, 8 a.m. to 8 p.m. Eastern time. Prescribers in Puerto Rico should call 1-866-488-5991.
Information about the launch of generic Exjade
Effective April 1, 2019, generic Exjade (deferasirox) is not covered for Humana’s Medicare Advantage prescription drug plan and Part D plan members; brand Exjade will continue to be covered with prior authorization (PA) and can be filled for the patient.
Prescribers with questions regarding this may call 1-800-555-CLIN (1-800-555-2546), Monday through Friday, 8 a.m. to 8 p.m. Eastern time. Prescribers in Puerto Rico should call 1-866-488-5991.
Impact of ongoing angiotensin II receptor blocker drug recalls
Impact of ongoing angiotensin II receptor blocker drug recalls
Drug recall notice for Novartis and Sandoz blister packs
Drug recall notice for Novartis and Sandoz blister packs
Med-Edit update notification
As of Jan. 1, 2018, Humana Pharmacy Solutions made enhancements to the opioid utilization program point-of-sale edits based on the opioid thresholds below. Please note: Patients with cancer or in hospice will not be flagged for this edit.